Gyroscope Therapeutics Holdings plc

General Information

We are a global clinical-stage gene therapy company developing gene therapy beyond rare diseases. Our mission is to preserve sight and fight the devastating impact of blindness. Our science is grounded in the genetic understanding of patients with serious eye diseases to make medicines designed to have a meaningful impact. Our initial focus is age-related macular degeneration, or AMD, one of the leading causes of irreversible blindness, affecting more than 196 million people worldwide. We are developing a differentiated pipeline of recombinant adeno-associated virus, or rAAV, gene therapy candidates targeting genetic variants in the complement pathway that we believe to be key drivers of AMD. Our investigational gene therapies are designed as one-time treatments. Our lead investigational gene therapy, GT005, is advancing in an ongoing Phase I/II clinical trial and is being evaluated in Phase II clinical trials in two different genetically defined patient populations with geographic atrophy, or GA, an advanced form of dry AMD. We have received Fast Track designation from the U.S. Food and Drug Administration, or the FDA, for GT005 for the treatment of GA secondary to AMD.

Employees: 167
Founded: 2016
Contact Information
Address Stevenage Bioscience Catalyst Gunnels Wood Road Stevenage, Hertfordshire, SG1 2FX United Kingdom
Phone Number + 44 (0)1438 906770
Web Address
View Prospectus: Gyroscope Therapeutics Holdings plc
Financial Information
Market Cap $613.83mil
Revenues $0.86 mil (last 12 months)
Net Income $-53.2 mil (last 12 months)
IPO Profile
Symbol VISN
Exchange NASDAQ
Shares (millions): 6.8
Price range $20.00 - $22.00
Est. $ Volume $141.8 mil
Manager / Joint Managers Morgan Stanley/ Goldman Sachs/ Citigroup
CO-Managers -
Expected To Trade: 5/7/2021
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change